Quick Answer
Transcode Therapeutics, Inc. reported Net Income Loss of -$16.75 million for the year ending 2024.
- Transcode Therapeutics, Inc. showed an increase of +9.7% in Net Income Loss from 2023 to 2024.
- This data is from Transcode Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$41.3 thousand | Q2 2020: -$127.2 thousand | Q3 2020: -$1.37 million | Q1 2021: -$4.49 million | Q2 2021: $2.77 million | Q3 2021: -$2.33 million | Q1 2022: -$3.47 million | Q2 2022: -$4.67 million | Q3 2022: -$4.29 million | Q1 2023: -$4.82 million | Q2 2023: -$4.34 million | Q3 2023: -$5.30 million | Q1 2024: -$3.33 million | Q2 2024: -$5.19 million | Q3 2024: -$2.32 million | Q1 2025: -$12.09 million | Q2 2025: -$4.28 million | Q3 2025: -$4.86 million.
- Over the full 5 years of available data (2020 to 2024), Transcode Therapeutics, Inc.'s Net Income Loss has declined by 614.8%.
- Historical annual values: Fiscal year 2024: -$16.75 million | Fiscal year 2023: -$18.55 million | Fiscal year 2022: -$17.56 million | Fiscal year 2021: -$6.84 million | Fiscal year 2020: -$2.34 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: